Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Histamine
Drug ID BADD_D01071
Description A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Indications and Usage Histamine phosphate is indicated as a diagnostic aid for the evaluation of gastric acid secretory function.
Marketing Status approved; investigational
ATC Code L03AX14
DrugBank ID DB05381
KEGG ID D08040
MeSH ID D006632
PubChem ID 774
TTD Drug ID D04USC
NDC Product Code 65044-9998; 63083-1522; 81701-111
UNII 820484N8I3
Synonyms Histamine | Peremin | Histamine Dihydrochloride | Histamine Hydrochloride | Ceplene
Chemical Information
Molecular Formula C5H9N3
CAS Registry Number 51-45-6
SMILES C1=C(NC=N1)CCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophilia01.02.04.001--
Erythema23.03.06.0010.000637%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastritis07.08.02.001--
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.001--
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injection site bruising23.03.11.015; 12.07.03.042; 08.02.03.042; 24.07.06.017--Not Available
Injection site dermatitis23.03.04.033; 12.07.03.041; 08.02.03.041--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site fibrosis08.02.03.025; 12.07.03.025--Not Available
Injection site granuloma23.03.15.003; 12.07.03.003; 08.02.03.003--Not Available
Injection site haemorrhage12.07.03.005; 24.07.01.010; 08.02.03.005--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injection site urticaria23.04.02.003; 12.07.03.029; 10.01.06.003; 08.02.03.029--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.003--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages